SIRPA and myelodysplastic syndrome: CSF1R inhibitor and anti-CD47 antibodies or anti-SIRPα antibodies have been applied for solid tumors and some hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndrome (MDS) (Weiskopf, 2017).